Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,713actual
Sites
335
Countries
Argentina, Australia, Belgium +34
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-06 | actual | When the study began enrolling |
| Primary completion | 2026-02-26 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-27 | actual | The whole study's end, after follow-up |
| First posted | 2023-02-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
- Combination product: Tozorakimab 1
- Combination product: Tozorakimab 2
- Combination product: Placebo
Primary outcome
what the primary-completion date above is the date OFAnnualised rate of severe COPD exacerbations in former smokers.
measured Up to 104 weeks.
Publications
- PMID 42476723 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed